PEX010 Psilocybin Capsules (25mg psilocybin)

DRUG4 trials

Sponsors

Amsterdam UMC, Association Hospitaliere De Bruxelles Et De Schaerbeek Centre Hospitalier Universitaire Brugmann, Universita' Degli Studi G. D'Annunzio Di Chieti

Conditions

Severe Alcohol Use DisorderTreatment Resistant Depression (TRD)Treatment-Resistant Depressionchemotherapy-induced peripheral neuropathychronic neuropathic pain

Phase 2

Soothing Pain After ChEmotherapy: Psilocybin As INtervention (SPACE-PAIN) — a randomized controlled pilot trial

RecruitingCTIS2024-516936-93-02

Amsterdam UMCchemotherapy-induced peripheral neuropathy, chronic neuropathic pain

Start: 2025-10-28Target: 50Updated: 2025-01-30

Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive Mechanisms

RecruitingCTIS2024-518061-10-00

Association Hospitaliere De Bruxelles Et De Schaerbeek Centre Hospitalier Universitaire BrugmannSevere Alcohol Use Disorder

Start: 2023-09-13Target: 62Updated: 2025-11-21

Advancing PRecise Interventions for resistant DEpression: rebalancing brain networks and investigating the trajectories of antidepressant effect with psilocybin and personalized neuromodulation (PRIDE)

Not yet recruitingCTIS2024-519844-34-03

Universita' Degli Studi G. D'Annunzio Di ChietiTreatment Resistant Depression (TRD)

Target: 68Updated: 2025-11-19

A phase IIa open-label dose-finding study with lead-in phase evaluating the safety, pharmacokinetics, and attenuating effects of trazodone on the consciousness-altering effects of psilocybin in individuals with Treatment-Resistant Depression

Not yet recruitingCTIS2025-523346-27-00

Universita' Degli Studi G. D'Annunzio Di ChietiTreatment-Resistant Depression

Target: 30Updated: 2026-08-14